MIM
ATNM icon

MetLife Investment Management’s Actinium Pharmaceuticals ATNM Stock Holding History

MetLife Investment Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,276
Closed -$113K – 2853
2024
Q2 		$113K Buy
15,276
+1,434
+10% +$11.8K ﹤0.01% 2547
2024
Q1 		$108K Hold
13,842
– – ﹤0.01% 2494
2023
Q4 		$70.3K Hold
13,842
– – ﹤0.01% 2734
2023
Q3 		$81.9K Hold
13,842
– – ﹤0.01% 2677
2023
Q2 		$103K Buy
+13,842
New +$118K ﹤0.01% 2666

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $25.4B AUM 38.46% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

MetLife Investment Management's ATNM Position: Q3 2024 in Review

MetLife Investment Management sold out of Actinium Pharmaceuticals (ATNM) in Q3 2024, closing a stake of 15,276 shares — an estimated $113K sold.

MetLife Investment Management first reported a position in ATNM in Q2 2023 and held it in 5 quarters. The position peaked at $113K in Q2 2024. 72 funds tracked by Wall St. Rank hold ATNM as of Q3 2024.

  • MetLife Investment Management reported no remaining Actinium Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • MetLife Investment Management sold 15,276 Actinium Pharmaceuticals shares in Q3 2024, an estimated $113K.
  • MetLife Investment Management first reported a position in Actinium Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • MetLife Investment Management's Actinium Pharmaceuticals position peaked at $113K in Q2 2024.
  • 72 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2024.

Based on MetLife Investment Management's 13F filing for Q3 2024, filed 13 Nov 2024.